Means affecting the structure and mineralization of bones. Bisphosphonates.
- Prevention of symptoms associated with damage to the bone tissue (pathological fractures, compression of the spinal trunk, complications after surgical interventions and radiation therapy, or hypercalcemia caused by a malignant tumor) in patients with malignant tumors in the later stages.
- Treatment of hypercalcemia caused by a malignant tumor.
Hypersensitivity to the active ingredient (Zoledronic acid), other bisphosphonates, or any excipients in the drug composition.
Pregnancy and lactation.
Transparent colorless liquid.
Store in original packaging at a temperature not higher than 25 °C. Keep out of the reach of children.